One-Stop Integrated Viral Vector Platform for Speed to Clinic
Summary: In this BPI Theater presentation, Catalent expert Carey Connelly discusses UpTempo℠ AAV, a one-stop integrated viral vector platform for speed to clinic. Discover how implementing the right process, utilizing a clonal HEK293 cell line, and leveraging a range of off-the-shelf plasmids, along with qualified analytical methods, can support a robust supply chain for the development and manufacture of AAV vectors. This approach not only helps in reducing timelines to clinical evaluation but also ensures efficient and effective production. The complete platform approach provides increased consistency and efficiency, reducing the time to manufacture clinical-quality drug product to just nine months, while delivering a process that will readily advance to late stage GMP manufacture.